Faricimab Maintains Long-Term Stability in Diabetic Macular Edema
Overview
Four-year data from the RHONE-X study demonstrate that faricimab provides sustained improvements in best-corrected visual acuity (BCVA) and central subfield thickness (CST) in patients with diabetic macular edema (DME). Over half of the patients achieved extended dosing intervals up to 20 weeks, with a favorable safety profile maintained throughout the study.
Background
Diabetic macular edema is a leading cause of vision loss in diabetic patients, requiring effective long-term management strategies. Faricimab, a bispecific antibody targeting angiopoietin-2 and VEGF-A, has shown promise in earlier 2-year studies (YOSEMITE and RHINE) for improving visual and anatomical outcomes in DME. The RHONE-X study extended follow-up to four years to assess the durability of faricimab’s efficacy and safety in a treat-and-extend dosing regimen.
Data Highlights
| Parameter | Finding |
|---|---|
| Percentage achieving 20-week dosing interval | >50% |
| BCVA and CST improvements | Maintained at 4 years |
| Time to CST < 325 µm | Faster with faricimab vs aflibercept |
| Hard exudate reduction after switch from aflibercept | Observed with faricimab |
| Safety profile | Consistent and well tolerated |
Key Findings
- More than 50% of patients on faricimab treat-and-extend achieved dosing intervals up to 20 weeks by year 4.
- BCVA and CST improvements observed in initial studies were sustained over the 4-year period.
- Patients initially treated with faricimab reached CST less than 325 µm faster and with fewer injections compared to those starting on aflibercept.
- Switching from aflibercept to faricimab led to further reduction in hard exudates, a marker of severe DME.
- Faricimab demonstrated a consistent safety profile with good tolerability over the long term.
Clinical Implications
Faricimab offers a durable treatment option for DME patients, enabling extended dosing intervals that may reduce treatment burden. Its ability to maintain visual and anatomical stability over four years supports its use in long-term management. Additionally, patients inadequately controlled on aflibercept may benefit from switching to faricimab to achieve further anatomical improvements.
Conclusion
The RHONE-X study confirms that faricimab provides sustained efficacy and safety in DME over four years, with potential for extended dosing intervals and improved anatomical outcomes even in patients previously treated with aflibercept.
References
- Sheth VS et al. 2025 -- Four-year RHONE-X Study Data on Faricimab in DME Presented at ASRS
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
